Cardiovascular Disease

Childhood Lp(a) Predicts Adult CVD Risk

Individuals who had high Lp(a) levels when they were young were twice as likely to develop atherosclerotic cardiovascular disease in middle age, a new study in Circulation reveals

Lp(a) levels are almost entirely genetic (as opposed to being dictated by lifestyle choices), and this new study underscores the value of measuring Lp(a) in childhood, rather than waiting till middle age to identify those most at-risk.

The authors examined Lp(a) data from the 1970s YFS study (n=3596), which investigated the determinants of CV disease in Finnish children, as well as data from the 1980s Bogalusa Heart Study (n=587) out of Tulane University.  

In the YFS analysis, the authors found that…

  • Those with high childhood Lp(a) levels (defined as 30 mg/dL or higher) were about twice as likely to develop adult ASCVD (hazard ratio: 2.0).
  • The risk of coronary heart disease and noncoronary atherosclerotic events were both similarly increased.

In the BHS analysis, researchers found that…

  • Individuals with high childhood Lp(a) were 2.5 times more likely to develop adult ASCVD.
  • The risk associated with Lp(a) remained the same, even after adjusting for BMI and LDL-C.

In neither study was Lp(a) in youth associated with increased carotid artery thickness in adulthood, which may suggest that elevated Lp(a) levels do not confer CV risk by contributing to early preclinical vasculopathy.

The generalizability of these findings is unclear. The results observed in the Finnish study were replicated with data exclusively from White participants in the BHS “because the original YFS included only White participants.” Cardiovascular risk is known to differ across racial/ethnic groups, causing risk equations to consistently underperform in Black adults. So take these findings with a grain of salt.  

The Takeaway

Elevated Lp(a) is a known atherosclerotic CVD risk factor, and these data suggest that measuring Lp(a) in youth would help identify individuals at higher risk for future ASCVD. Although Lp(a) levels cannot be modified by lifestyle or diet, it appears to be important to emphasize heart-healthy lifestyle choices if elevated levels are detected during childhood.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions June 23, 2025

Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!